A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation
John T. Brandt(Universitätsklinikum Würzburg), Kenneth J. Winters(Eli Lilly (United States)), Nagy A. Farid(Eli Lilly (United States)), Govinda Weerakkody(Eli Lilly (United States)), Stephen D. Wiviott(Brigham and Women's Hospital), Joseph A. Jakubowski(Indiana Biosciences Research Institute), Hideo Naganuma(Daiichi-Sankyo (Japan)), David S. Small(Eli Lilly (United States)), Christopher D. Payne(Eli Lilly (United States))
Cited by 571
Related Papers
Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2007|6.7k
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2018|6.3k
Edoxaban versus Warfarin in Patients with Atrial Fibrillation
|New England Journal of Medicine|2013|5.2k
Rivaroxaban in Patients with a Recent Acute Coronary Syndrome
|New England Journal of Medicine|2011|1.9k
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
|New England Journal of Medicine|2015|1.5k